Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Terminated 4Completed 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1Genitourinary 1

Conditions

Recurrence 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Liposarcoma 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Terminated × plitidepsin × Clear all
NCT01876043 2021-01-25

APLIPO

Institut Bergonié

Phase 2 Terminated
24 enrolled 10 charts
Sarcoma

Liposarcoma, Neoplasm Metastasis, Recurrence

NCT03117361 2020-12-02

Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

PharmaMar

Phase 2 Terminated
10 enrolled 37 charts
Plasma cell

Multiple Myeloma

NCT00780975 2020-11-24

A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

PharmaMar

Phase 2 Terminated
8 enrolled 9 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03070964 2020-10-14

A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

PharmaMar

Phase 2 Terminated
14 enrolled 21 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡